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Background: Suicide is a major problem in schizophrenia, estimated to affect 9%–13% of 
patients. About 25% of schizophrenic patients make at least one suicide attempt in their life-
time. Current outcome measures do not address this problem, even though it affects quality of 
life and patient safety. The aim of this study was to assess suicidality in long-term clinically 
improved schizophrenia patients who were treated in a nongovernmental psychiatric treatment 
centre in Mumbai, India.
Method: Participants were 61 patients out of 200 consecutive hospitalized first-episode patients 
with schizophrenia diagnosed according to the Diagnostic and Statistical Manual of Mental 
Disorders who were much improved on the Clinical Global Impression Scale-Improvement 
(CGI-I) scale at the endpoint of a 10-year follow-up. Clinical assessment tools included the 
Positive and Negative Syndrome Scale for Schizophrenia, CGI-I, Global Assessment of Func-
tioning, and suicidality.
Results: Many of the patients, although clinically improved, experienced emerging suicidality 
during the 10-year follow-up period. All of the patients reported significant suicidality (ie, suicide 
attempts, suicidal crises, or suicidal ideation) at the end of the study, whereas only 83% had 
reported previous significant suicidality at baseline. No sociodemographic and clinical variables 
at baseline were predictive of suicidal status at the end of the 10-year follow-up.
Conclusion: Schizophrenia is a complex neurobehavioral disorder that appears to be closely 
associated with suicidal behavior. Adequate assessment and management of suicidality needs 
to be a continual process, even in patients who respond well to treatment.
Keywords: schizophrenia, suicide risk, prevention
Introduction
Suicide is a major cause of premature death among patients suffering from schizo-
phrenia.1,2 Miles reviewed 34 studies of suicide among schizophrenia patients and 
estimated that 10% of them complete suicide.3 Follow-up studies have estimated that 
10%–13% of individuals with schizophrenia die by suicide, which is the main cause 
of death among these patients.4 However, a recent meta-analysis estimated that only 
about 5% of schizophrenia patients commit suicide,5 a percentage which surprised 
many researchers because it was lower than previously thought. Regardless, it is still 
an unacceptably high rate. Inskip et al performed a meta-analysis on suicide among 
patients with affective disorder, alcoholism, and schizophrenia, and estimated that 
the lifetime risk of suicide was 6% for affective disorder, 7% for alcohol dependence, 
and 4% for schizophrenia,6 an estimate for schizophrenia that is consistent with the 





in schizophrenia patients may be as high as 1% per year for 
the next five years.7,8 Pompili et al reviewed the literature 
on suicide among inpatients with schizophrenia and found 
that the suicide rate in schizophrenia patients followed up 
after the first hospitalization for periods ranging from 1 to 
26 years was 6.8%.9
Harris and Barraclough included 28 studies in their meta-
analysis and found that the risk of suicide among patients 
diagnosed with schizophrenia exceeded that in the general 
population by more than eight-fold (standardized mortality rate 
[SMR] 8.45, confidence interval 7.98–8.95).10 Brown found that 
schizophrenia was associated with excess death from both natu-
ral causes (such as respiratory diseases) and unnatural causes 
(accidents, suicide, and homicide).11 Suicide accounted for 12% 
of all deaths among schizophrenia patients and about 28% of all 
excess deaths. According to Brown, the excess mortality was 
highest in first-episode or early-illness phase patients, indicating 
a high rate of suicide early in the illness. Danish studies that 
assessed SMRs in successive national cohorts suggest that the 
SMR may be rising in first-episode schizophrenia patients in 
Denmark and falling in chronic schizophrenia patients.12,13
At the same time, other data indicate that suicide risk may 
be elevated across the entire course of schizophrenia. A recent 
examination of suicides in all patients with schizophrenia in 
Finland over a 12-month period found that one-third of sui-
cides occurred in patients over the age of 45 years.14 Despite 
great efforts, using both drug treatments and psychosocial 
strategies, the number of suicides among schizophrenia 
patients has remained unchanged,15 although Nordentoft 
et al have shown that suicide among Danish patients with 
schizophrenia has fallen, paralleling the reduction of suicide 
in the general population.16
The stress-diathesis suicide-risk model is helpful for 
understanding suicidal behavior and its management in 
schizophrenia.17 In this model, suicide risk factors may be 
either distal or proximal. Distal risk factors create a predis-
posing diathesis and determine the patient’s response to a 
stressor. They include developmental, personality, biologic, 
and genetic variables. They affect the threshold for suicide, 
and increase the risk of suicide in schizophrenia when the 
patient experiences a proximal risk factor. Proximal (ie, trig-
ger) factors are more closely related to suicidal behavior and 
act as precipitants. They include life events and, relevant to 
schizophrenia patients, the stress of acute episodes of men-
tal illness, such as when relapsing into psychosis. Suicidal 
schizophrenia patients differ from nonsuicidal patients in 
distal risk factors (such as childhood trauma), and their 
risk of suicidal behavior may be increased by proximal risk 
factors, such as an exacerbation of illness caused by treatment 
noncompliance, adverse life events, or comorbid substance 
abuse and depression, as well as sleep problems.18
The present paper examines the presence of suicidality 
in a cohort of clinically improved patients with first-episode 
schizophrenia followed up for 10 years. The objective was to 
assess whether, with continuous treatment, suicidal thoughts, 




This study was conducted in a nongovernmental psychiatric 
treatment center (licensed under the Indian Mental Health 
Act, 1987) in Mumbai, India. Ethics permission was obtained 
from the local independent research ethics board. Appropriate 
consents were received from all patients.
Sample and study design
Two hundred consecutive, hospitalized, first-episode patients 
entered a long-term follow-up study. Almost half (49%) of 
the patients were lost during the 10-year follow-up which, 
although high, appears to be a general pattern in patients with 
early psychosis.13 Patients available at the endpoint of 10 years 
and rated as “improved” and “much improved” (n = 61), as 
measured by the Clinical Global Impression Scale-Improve-
ment (CGI-I), were recruited for the present study to assess the 
presence of suicidal behavior. Forty-three (73%) of the patients 
were male, and the mean duration of illness prior to treatment 
was 14.0 months, with a standard deviation of ± 8.0.
To assess suicide risk, we used a measurement scale of 
1 to 5 (1 being the lowest value and 5 being the highest). 
This semistructured scale has been tested in local conditions 
and used in other studies.19 We compared the characteristics 
of the patients and treatment variables at baseline and at 
follow-up.
Measures
Clinical assessment of patients was conducted using the 
Positive and Negative Syndrome Scale for Schizophrenia 
(PANSS),20 CGI,21 and Global Assessment of Functioning 
(GAF).22 The CGI was developed for use in clinical trials 
sponsored by the National Institutes of Mental Health to 
provide a brief, stand-alone assessment of the clinician’s 
view of the patient’s global functioning prior to and after 
initiating a study medication.21 The scale provides an over-
all clinician-determined summary measure that takes into 
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the patient’s history, psychosocial circumstances, symptoms, 
behavior, and impact of symptoms on the patient’s ability to 
function. The CGI comprises two dimensions, ie, severity of 
psychopathology (CGI-S) and improvement after initiation of 
treatment (CGI-I). Both dimensions are rated on a seven-point 
Likert-type scale (from 1 “very much improved” to 7 “very 
much worse since the initiation of treatment” for the CGI-I, 
and from 1 “normal” to 7 “among the most extremely ill 
patients” for the CGI-S).
Suicidality was rated by clinical interviews and a review 
of medical files. Subjects were categorized in one of the 
following classes:
•	 Attempted suicide – a potentially self-injurious behavior, 
associated with at least some intent to die as a result of the 
act; evidence that the individual intended to kill himself/
herself, at least to some degree, can be explicit or inferred 
from the behavior or circumstance; a suicide attempt may 
or may not result in actual injury
•	 Experiencing a suicidal crisis – preparatory acts toward 
imminent suicidal behavior; the individual takes steps to 
injure himself or herself but is stopped by self or others 
from starting the self-injurious act before the potential 
for harm has started
•	 Contemplating suicide – active thoughts about killing 
oneself, not accompanied by preparatory behavior
•	 Occasional death wishes – passive thoughts about wanting 
to be dead
•	 No suicidal intent – an outcome free from suicidality 
defined as the absence of any suicidal behavior or ide-
ation, or occasional presence of death wish.
Fifty-five percent of patients were on monotherapy, 25% 
were on two or more antipsychotics, including a combination 
of two atypicals in 18% of cases. Percent usage pattern and 
daily mean dosage (available for about 88% of the patients) 
was 23% (295 mg) for clozapine, 7.4% (5.3 mg) for ris-
peridone, 7.6% (17.6 mg) for olanzapine, 10.4% (558 mg) 
for quetiapine, 23.8% (16 mg) for aripiprazole, and 5.7% 
(112 mg) for ziprasidone.
Statistical methods
We used signed rank tests for comparisons between base-
line versus the end of the study, and one-way analyses of 
variance and Chi-square tests (χ2) for comparisons between 
independent groups (patients who attempted suicide dur-
ing the study, those who experienced suicidal crisis, and 
those who had suicidal ideation). Because a higher number 
of analyses may increase Type I errors (the probability of 
accepting the alternative hypothesis when it is not true), 
we corrected our results with a Bonferroni correction for 
multiple testing. The data were analyzed using SAS version 
9.1 (SAS Institute, Cary, NC). Probability values less than 
0.05 were considered to be statistically significant.
Results
Table 1 lists the baseline characteristics of the sample 
of clinically improved schizophrenia patients who had 
moderate to severe symptomatology at admission (PANSS 
108.5 ± 14.2; positive symptoms 29.6 ± 5.2; negative symp-
toms 20.9 ± 6.4) and severe limitation of social and work 
  functioning (GAF 48.0 ± 10.9).
About 83% of patients reported a previous suicide attempt, 
suicidal crisis, or suicidal ideation (24% reported previous sui-
cide attempts, 26% reported experience of a suicidal crisis, and 
33% reported suicidal ideation). At the end of the study, 100% 
of patients reported a suicide attempt, suicidal crisis, or suicidal 
ideation during the course of the study (see Table 2). Thus, 
despite the fact that all patients were assessed as improved or 
much improved on the CGI-I between the baseline evaluation 
and the end of the study, suicidality increased significantly 
(P , 0.001). About 72% of patients had attempted suicide 
or experienced a suicidal crisis since the first hospitalization, 
whereas only 50% of patients reported having attempted 
suicide or experiencing a suicidal crisis before the first hos-
pitalization. This figure indicates that many schizophrenia 
patients who are considered to be clinically improved experi-
ence emerging suicidality during treatment. Because most 
patients experienced emerging suicidality (suicidal behavior or 
ideation), a prior suicide attempt was not a good predictor of 
suicidality during the treatment phase. No sociodemographic 
and clinical variables at baseline were associated with suicidal 
status at the end of the study (see Table 3). PANSS was signifi-
cant only before correcting for multiple testing.
Table 1 Baseline characteristics of schizophrenia patients (n = 61)
Characteristic Mean (SD) or 
frequency (%)
Age at intake (years) 31.8 (7.6)
Duration of illness (months) 14.0 (8.0)
Men 43 (70.5%)
PANSS total 108.5 (14.2)
PANSS PS 29.6 (5.2)
PANSS NS 20.9 (6.4)
PANSS disorganization (.3) 52 (86.7%)
cgi-S 5.6 (1.0)
gAF 48.0 (10.9)
Abbreviations: PANSS, Positive and Negative Syndrome Scale for Schizophrenia; 
cgi-S, clinical global impression Scale-improvement-Severity; NS, negative symptoms; 
PS,  positive  symptoms;  gAF,  global  Assessment  of  Functioning;  SD,  standard 





Furthermore, neither untreated illness duration before first 
hospitalization (less versus more than six months) nor age 
at intake (,24 years versus .25 years) was associated with 
subsequent suicidality (not reported in the tables).
Thus, baseline severity of symptomatology, positive 
and negative symptoms, and global functioning in daily life 
(as well as gender, age, and duration of untreated illness 
before first hospitalization) may not help clinicians predict 
suicidality in schizophrenia patients. The mean positive 
symptoms score was reduced by more than 65% between 
baseline and the end of the study. Negative symptoms were 
also reduced, but to a much lesser degree than were posi-
tive symptoms. It was observed that 23%–25% of patients 
showed social recovery on two or three parameters (life 
functioning, employability, interpersonal functioning, and 
ability to live independently). Basically, clinical symptoms 
improved but, in terms of social outcome, improvements 
were not as robust.
Discussion
The aim of this study was to assess suicide risk in first-episode 
schizophrenia patients during a 10-year follow-up period. 
Surprisingly, patients who improved in the psychopathologic 
components of their disorder were at high risk of suicide. One 
of the main issues in contemporary psychiatry is the fact that 
treating schizophrenia does not necessarily mean that proper 
suicide prevention is taken into account.
The lack of association between suicide and psychiatric 
disorders has been documented in many studies.23,24 The 
conclusion derived from psychological autopsy studies, 
namely that the vast majority of individuals who die by 
suicide suffered from a mental disorder at the time of their 
death, has been shown to suffer from several biases.25 First, 
scholars worldwide use the term psychological autopsy for 
any retrospective investigation. Such studies lack compre-
hensive data from interview of key persons. It is rather easy 
to classify a person as depressed when in fact he or she was 
understandably sad over the state of his or her life. Most of 
the data obtained in psychological autopsy studies are derived 
from a forensic examination, physician, or death register, 
and much less often from family members or friends who 
could make sense of the depressive features which are dis-
tinguishable from clinical depression. Suicide is a problem 
of the human condition or, as Shneidman points out “ … a 
dissatisfaction of the status quo”.26,27
Scholars have come to believe that alternative theoretical 
models must be found, because the vast majority of depressed, 
schizophrenic, alcoholic, or organically psychotic patients do 
not attempt or complete suicide.28–30 Much suicide research 
focuses on psychiatric patients, but ignores the cry for help 
that results from loss, humiliation, failure, and shame.26
Therefore, one of the errors in suicide prevention is 
the assumption that treating a psychiatric disorder will 
also reduce suicide risk. The evidence supports instead the 
Table 2 Suicidality at baseline and the end of the study
Suicidality Baseline End of study
Attempted suicide 15 (24.1%) 30 (48.3%)
Suicidal crisis 16 (25.9%) 14 (23.3%)
Suicidal ideation 20 (32.8%) 17 (28.3%)
Death wish 7 (12.1%) 0 (0.0%)
None 3 (5.2%) 0 (0.0%)
Notes: For difference between baseline and end of study, P , 0.001, signed rank test.









Test statistic P value
Age at intake  
(years)
32.5 (7.0) 31.6 (9.8) 30.6 (6.6) F (2,57) = 0.34 0.72 
Duration of illness  
(months)
13.9 (8.1) 13.9 (7.5) 14.2 (8.9) F (2,57) = 0.01 0.99
Male gender 18 (60.0%) 10 (71.4%) 14 (82.4%) χ2 (df = 2) = 1.61 0.45
PANSS 106.5 (14.3) 103.4 (11.8) 115.8 (14.1) F (2,57) = 3.67 0.03
PS 28.6 (6.0) 30.5 (3.9) 30.8 (4.6) F (2,57) = 1.19 0.31
NS 21.7 (6.6) 21.7 (5.6) 19.2 (6.5) F (2,57) = 0.94 0.40
Abnormal  
disorganization (.3)
25 (83.3%) 10 (71.4%) 16 (94.1%) χ2 (df = 2) = 1.51 0.47
cgi-S at baseline 5.6 (1.0) 5.6 (1.0) 5.5 (0.8) F (2,57) = 0.07 0.94
gAF 49.4 (9.6) 50.8 (11.4) 43.3 (11.6) F (2,57) = 2.41 0.10
Notes: Bonferroni corrected P value: 0.05/11 = 0.005.
Abbreviations: PANSS, Positive and Negative Syndrome Scale for Schizophrenia; cgi-S, clinical global impression Scale-improvement-Severity; NS, negative symptoms; 
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notion that suicide prevention requires more than psychiatric 
treatment.23,24,31 The results of the present study indicate that 
clinical improvement is not a key element in decreasing suicide 
risk. On the contrary, improvement in schizophrenia symptoms 
may increase suicidality. Given the fact that improvement of the 
psychosis may lead to awareness of the illness, suicide risk may 
be the result of painful insight into one’s own impairment.32
Suicide prevention requires specific inquiry which must 
involve careful attention to suicidal risk and protective fac-
tors, as well as exploring warning signs for suicide, such 
as talking about suicide and death and having no reason to 
live. Most suicidal individuals give definite warnings of their 
suicidal intention, but significant others are either unaware 
of the significance of these warnings or do not know how to 
respond to them. Suicidal individuals may withdraw from 
friends and social activities and may have a recent severe 
loss (especially a relationship) or a threat of a significant loss. 
Moreover, they may show drastic changes in behavior and 
lose interest in hobbies, work, and school, as well as increas-
ing their use of alcohol or drugs and showing unwillingness 
to “connect” with potential helpers.
Hopelessness has been reported to be a more important 
indicator than depression of suicide risk. Studies using 
the Beck Hopelessness Scale have found that the extent of 
negative attitudes about the future (pessimism) was a better 
predictor of suicidal intent than depression.33,34
Drake et al have pointed to the need for empathic sup-
port in reducing suicide risk.35 These authors suggested that 
clinicians should acknowledge the patient’s despair, discuss 
losses and daily difficulties, and help the patient establish 
new and accessible goals.
Behavior of medical staff is a potential cause of suicide 
when staff members fail to recognize suicide risk because 
of personal problems or difficulties with the topic of suicide. 
Pompili et al pointed to the role of nurses in the prevention of 
suicide in schizophrenia.36,37 These authors outlined the many 
difficulties in the care of a schizophrenic patient who is at risk 
of suicide, and drew attention to staff “countertransference” 
reactions to these patients. A relevant concept is “terminal 
malignant alienation”.38,39 Some patients, particularly those 
with recurrent relapses and resistance to treatment, may be 
perceived by staff as manipulative, provocative, unreason-
able, overdependent, and feigning disability.38–40 Patients 
with fluctuating suicidal ideation are particularly likely to 
fall into these categories, and this may lead to underreport-
ing of suicidal ideation by nursing staff. This may result in a 
critical attitude toward patients and a lower level of support, 
leading to alienation. The combination of such alienation and 
fluctuating suicidal ideation can lead to failure to recognize 
the seriousness of suicide risk.38,39
A proper treatment regimen is of paramount importance 
for reducing suicide risk among schizophrenia patients. 
Clozapine is associated with the strongest antisuicidal effect 
when compared with other pharmacologic agents.41 Elec-
troconvulsive treatment, lithium therapy, and psychosocial 
interventions are also of great importance for reducing 
suicide risk.1
The present study has a number of limitations, including a 
small sample size, lack of a widely used instrument to assess 
suicide risk, and the cross-sectional nature of the study in a 
naturalistic clinical setting. These limitations impair gener-
alization of the results. Lastly, we did not analyze exacerba-
tions of illness during the 10-year treatment, which may be 
associated with emergent suicidality. However, our analysis 
points to the absence of long-term predictors for suicide 
risk when assessing the clinical status of schizophrenia   
patients.
Despite these caveats, our study points to a core problem 
in dealing with schizophrenia patients. Clinicians should be 
aware of the unique nature of suicidality which accompanies 
the psychiatric disorder, but which may be independent of 
the disorder. Specific inquiry into a patient’s suicide risk is 
required in order to initiate measures to prevent suicide dur-
ing the treatment of schizophrenia. Suicide might be better 
understood as phenomenon-centered in the individual, ie, the 
motives for suicide can be traced to the variables surrounding 
the individual viewed as a unique human being whose per-
sonality contains the real reasons for wishing suicide.42,43
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